CN116731046A - 一种高活性的hpk1激酶抑制剂 - Google Patents
一种高活性的hpk1激酶抑制剂 Download PDFInfo
- Publication number
- CN116731046A CN116731046A CN202310687571.6A CN202310687571A CN116731046A CN 116731046 A CN116731046 A CN 116731046A CN 202310687571 A CN202310687571 A CN 202310687571A CN 116731046 A CN116731046 A CN 116731046A
- Authority
- CN
- China
- Prior art keywords
- salts
- compound
- reaction
- compounds
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000694 effects Effects 0.000 title abstract description 11
- 229940125962 HPK1 kinase inhibitor Drugs 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 67
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
- 230000001404 mediated effect Effects 0.000 claims abstract description 8
- 201000011510 cancer Diseases 0.000 claims abstract description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 5
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 5
- 238000011282 treatment Methods 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 230000002265 prevention Effects 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 3
- 230000000155 isotopic effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 101001059991 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 1 Proteins 0.000 abstract description 10
- 102100028199 Mitogen-activated protein kinase kinase kinase kinase 1 Human genes 0.000 abstract description 10
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 39
- 238000006243 chemical reaction Methods 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 25
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 238000000034 method Methods 0.000 description 17
- 239000000203 mixture Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 239000000543 intermediate Substances 0.000 description 13
- -1 small molecule compounds Chemical class 0.000 description 12
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 239000012453 solvate Substances 0.000 description 10
- 102000000588 Interleukin-2 Human genes 0.000 description 9
- 108010002350 Interleukin-2 Proteins 0.000 description 9
- 238000005481 NMR spectroscopy Methods 0.000 description 9
- 239000012980 RPMI-1640 medium Substances 0.000 description 9
- 210000004443 dendritic cell Anatomy 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 101001090688 Homo sapiens Lymphocyte cytosolic protein 2 Proteins 0.000 description 4
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 description 4
- 230000006044 T cell activation Effects 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 150000004677 hydrates Chemical class 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- FNVOFDGAASRDQY-UHFFFAOYSA-N 3-amino-2,2-dimethylpropan-1-ol Chemical compound NCC(C)(C)CO FNVOFDGAASRDQY-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000003727 ADP Glo Kinase Assay Methods 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 102000008016 Eukaryotic Initiation Factor-3 Human genes 0.000 description 2
- 108010089790 Eukaryotic Initiation Factor-3 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 101100446506 Mus musculus Fgf3 gene Proteins 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 101000767160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Intracellular protein transport protein USO1 Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 150000002823 nitrates Chemical class 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- NNWUEBIEOFQMSS-ZCFIWIBFSA-N (2r)-2-methylpiperidine Chemical group C[C@@H]1CCCCN1 NNWUEBIEOFQMSS-ZCFIWIBFSA-N 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- QARVELJVEBLWGK-UHFFFAOYSA-N 1-methyl-3,5-dinitropyridin-2-one Chemical compound CN1C=C([N+]([O-])=O)C=C([N+]([O-])=O)C1=O QARVELJVEBLWGK-UHFFFAOYSA-N 0.000 description 1
- HUUPVABNAQUEJW-UHFFFAOYSA-N 1-methylpiperidin-4-one Chemical compound CN1CCC(=O)CC1 HUUPVABNAQUEJW-UHFFFAOYSA-N 0.000 description 1
- 102000004899 14-3-3 Proteins Human genes 0.000 description 1
- QTLHJKSNSNAIIC-UHFFFAOYSA-N 2-(1-methylcyclopropyl)ethanamine Chemical group NCCC1(C)CC1 QTLHJKSNSNAIIC-UHFFFAOYSA-N 0.000 description 1
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 1
- RDXIMGMWNHHMQU-UHFFFAOYSA-N 3,4,4a,5-tetrahydro-1h-1,6-naphthyridin-2-one Chemical compound C1N=CC=C2NC(=O)CCC21 RDXIMGMWNHHMQU-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical class OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical class OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- KHWWIVGXOLWGMI-UHFFFAOYSA-N CC1(CNC2=NC=CC3=C2N=C(NC2=CC(CN(C)CC4)=C4NC2=O)N=C3)CC1 Chemical compound CC1(CNC2=NC=CC3=C2N=C(NC2=CC(CN(C)CC4)=C4NC2=O)N=C3)CC1 KHWWIVGXOLWGMI-UHFFFAOYSA-N 0.000 description 1
- 101100177670 Caenorhabditis elegans hpk-1 gene Proteins 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 101000760079 Homo sapiens 14-3-3 protein epsilon Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical class [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical class [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 101100268066 Mus musculus Zap70 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- NINIDFKCEFEMDL-AKLPVKDBSA-N Sulfur-35 Chemical compound [35S] NINIDFKCEFEMDL-AKLPVKDBSA-N 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001278 adipic acid derivatives Chemical class 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical class O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- 125000003277 amino group Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 150000001509 aspartic acid derivatives Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 150000004652 butanoic acids Chemical class 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical class [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical class CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 150000002085 enols Chemical group 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 150000002315 glycerophosphates Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical class CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical class CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical class OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical class OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000011777 magnesium Chemical class 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 150000006636 nicotinic acid Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical class CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical class CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Chemical class 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical group C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical class CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本发明提供了一种具有抑制HPK1激酶活性的化合物以及包含所述化合物的药物组合物。本发明还提供了所述化合物在预防和/或治疗癌症、肿瘤、炎症性疾病、自身免疫性疾病或免疫介导性疾病中的用途。
Description
技术领域
本发明涉及一种杂环化合物，具体地涉及一种高活性的HPK1激酶抑制剂及其用途。
背景技术
HPK1是MAP4K家族的成员之一，主要在造血系统细胞中表达，并且充当T细胞增殖和信号传导的细胞内负调节物。抗原刺激T细胞后促使胞浆中的接头蛋白SLP-76被招募到脂膜TCR复合体上，为信号转导相关激酶提供结合位点来实现TCR介导的信号传递而诱导T细胞激活。在这一过程中HPK1被酪氨酸激酶Lck和Zap70磷酸化而激活，参与调节T细胞受体蛋白相互作用。HPK1通过磷酸化接头蛋白SLP-76的Ser376位点，使得SLP-76与支架蛋白14-3-3ε结合进而通过蛋白酶体被降解，而这一效应使得SLP-76与信号转导相关激酶结合减少而阻断了TCR信号转导，继而抑制T细胞激活和增值。另一方面，HPK1还参与了调控树突状细胞(DCs)的成熟及激活，特别是抑制了DCs细胞中协助T细胞激活相关蛋白如CD80，CD86及MHC复合物等的表达，进而影响DCs调节T细胞激活的作用；而活化的DCs对肿瘤抗原的呈递及DCs和T细胞的相互协作是抗肿瘤免疫系统中最重要的环节之一。此外在肿瘤微环境中存在大量免疫抑制性的分子如PGE2和TGF－β，这些因子介导的免疫抑制作用也与HPK1有重要联系。总体而言，特异性靶向抑制HPK1的小分子化合物可通过以改善T细胞功能为主，增强DCs细胞功能并同时逆转肿瘤免疫抑制微环境等多途径发挥增强抗肿瘤免疫效应来发挥抑制肿瘤生长的作用。
发明内容
本发明提供了具有如下结构的化合物及其药学上可接受的盐、溶剂合物或者水合物：
特别注意的是，在本文中，当提及具有特定结构式的“化合物”时，一般地还涵盖其立体异构体、非对映异构体、对映异构体、外消旋混合物和同位素衍生物。
本领域技术人员公知，一种化合物的盐、溶剂合物、水合物是化合物的替代性存在形式，它们都可以在一定条件下转化为所述化合物，因此，特别注意的是在本文中当提到一种化合物时，一般地还包括它的可药用盐，进而还包括其溶剂合物和水合物。
相似地，在本文中当提到一种化合物时，一般地还包括其前药、代谢产物和氮氧化物。
本发明所述的可药用盐可使用例如以下的无机酸或有机酸而形成：“可药用盐”是指这样的盐，在合理的医学判断范围内，其适用于接触人和较低等动物的组织，而没有不适当的毒性、刺激性、过敏反应等，称得上合理的受益/风险比。可以在本发明化合物的最终分离和纯化期间原位制备所述盐，或单独通过将游离碱或游离酸与合适的试剂反应制备所述盐，如下概述。例如，游离碱功能可以与合适的酸反应。此外，当本发明的化合物带有酸性部分，其合适的可药用盐可包括金属盐，例如碱金属盐(如钠盐或钾盐)；和碱土金属盐(如钙盐或镁盐)。可药用的无毒酸加成盐的示例是氨基与无机酸(例如，盐酸、氢溴酸、磷酸、硫酸和高氯酸)或有机酸(例如，醋酸、草酸、马来酸、酒石酸、柠檬酸、琥珀酸或丙二酸)形成的盐，或通过使用现有技术中的其他方法如离子交换形成的盐。其他可药用盐包括己二酸盐、海藻酸钠、抗坏血酸盐、天门冬氨酸盐、苯磺酸盐、苯甲酸盐、硫酸氢盐、硼酸盐、丁酸盐、樟脑酸盐、樟脑磺酸盐、柠檬酸盐、环戊烷丙酸盐、二葡糖酸盐、十二烷基硫酸盐、乙磺酸盐、甲酸盐、富马酸盐、葡庚糖酸盐、甘油磷酸盐、葡萄糖酸盐、hernisulfate、庚酸盐、己酸盐、氢碘酸盐、2-羟基-乙磺酸盐、乳糖酸盐、乳酸盐、月桂酸盐、月桂基硫酸盐、苹果酸盐、马来酸盐、丙二酸盐、甲磺酸盐、2-萘磺酸盐、烟酸盐、硝酸盐、油酸盐、草酸盐、棕榈酸盐、扑酸盐、果胶酸盐、过硫酸盐、3-苯丙酸盐、磷酸盐、苦味盐、新戊酸盐、丙酸盐、硬脂酸盐、琥珀酸盐、硫酸盐、酒石酸盐、硫氰酸盐、对甲苯磺酸盐、十一酸盐、戊酸盐等。代表性碱金属或碱土金属盐包括钠、锂、钾、钙、镁等的盐。其他可药用盐包括(适当时)无毒铵盐、季铵盐和用反离子形成的胺阳离子，例如，卤化物、氢氧化物、羧酸盐、硫酸盐、磷酸盐、硝酸盐、低级烷基磺酸盐和芳基磺酸盐。
本发明的可药用盐可通过常规方法制备，例如通过将本发明的化合物溶解于与水可混溶的有机溶剂(例如丙酮、甲醇、乙醇和乙腈)，向其中添加过量的有机酸或无机酸水溶液，以使得盐从所得混合物中沉淀，从中除去溶剂和剩余的游离酸，然后分离所沉淀的盐。
本发明所述的“溶剂合物”意指本发明化合物与一个或多个溶剂分子(无论有机的还是无机的)的物理缔合。该物理缔合包括氢键。在某些情形中，例如当一个或多个溶剂分子纳入结晶固体的晶格中时，溶剂化物将能够被分离。溶剂化物中的溶剂分子可按规则排列和/或无序排列存在。溶剂合物可包含化学计量或非化学计量的溶剂分子。“溶剂合物”涵盖溶液相和可分离的溶剂合物。示例性溶剂合物包括但不限于水合物、乙醇合物、甲醇合物和异丙醇合物。溶剂化方法是本领域公知的。
本发明所述的“立体异构”分为构象异构和构型异构，构型异构还可分为顺反异构和旋光异构(即光学异构)，构象异构是指具有一定构型的有机物分子由于碳、碳单键的旋转或扭曲而使得分子各原子或原子团在空间产生不同的排列方式的一种立体异构现象，常见的有烷烃和环烷烃类化合物的结构，如环己烷结构中出现的椅式构象和船式构象。“立体异构体”是指当本发明化合物含有一个或多个不对称中心，因而可作为外消旋体和外消旋混合物、单一对映异构体、非对映异构体混合物和单一非对映异构体。本发明化合物有不对称中心，每个不对称中心会产生两个光学异构体，本发明的范围包括所有可能的光学异构体和非对映异构体混合物和纯的或部分纯的化合物。本发明所述的化合物可以以互变异构体形式存在，其通过一个或多个双键位移而具有不同的氢的连接点。例如，酮和它的烯醇形式是酮-烯醇互变异构体。各互变异构体及其混合物都包括在本发明的化合物中。所有式(I)化合物的对映异构体、非对映异构体、外消旋体、内消旋体、顺反异构体、互变异构体、几何异构体、差向异构体及其混合物等，均包括在本发明范围中。
本发明的“同位素衍生物”是指在本专利中化合物被同位素标记的分子。通常用作同位素标记的同位素是：氢同位素，2H和3H；碳同位素：11C,13C和14C；氯同位素：35Cl和37Cl；氟同位素：18F；碘同位素：123I和125I；氮同位素：13N和15N；氧同位素：15O,17O和18O和硫同位素35S。这些同位素标记化合物可以用来研究药用分子在组织中的分布情况。尤其是氘3H和碳13C，由于它们容易标记且方便检测，运用更为广泛。某些重同位素，比如重氢(2H)，的取代能增强代谢的稳定性，延长半衰期从而达到减少剂量的目而提供疗效优势的。同位素标记的化合物一般从已被标记的起始物开始，用已知的合成技术象合成非同位素标记的化合物一样来完成其合成。
本发明还提供了本发明化合物在制备用于预防和/或治疗癌症、肿瘤、炎症性疾病、自身免疫性疾病或免疫介导性疾病的药物中的用途。
此外，本发明提供了用于预防和/或治疗癌症、肿瘤、炎症性疾病、自身免疫性疾病、神经退行性疾病、注意力相关疾病或免疫介导性疾病的药物组合物，其包含本发明化合物作为活性成分。
此外，本发明提供了一种用于预防和/或治疗癌症、肿瘤、炎症性疾病、自身免疫性疾病、神经退行性疾病、注意力相关疾病或免疫介导性疾病的方法，其包括向有此需要的哺乳动物施用本发明化合物。
当将本发明化合物或其可药用盐与另外的用于治疗癌症或肿瘤的抗癌剂或免疫检查点抑制剂组合施用时，本发明化合物或其可药用盐可提供增强的抗癌作用。
当将本发明化合物或其可药用盐与另外的用于治疗炎症性疾病、自身免疫性疾病和免疫介导性疾病的治疗剂组合施用时，本发明化合物或其可药用盐可提供增强的治疗作用。
本发明描述示例性实施方案的过程中，本发明的其它特征将变得显而易见，给出所述实施方案用于说明本发明而不意欲成为其限制，以下实施例使用本发明所公开的方法制备、分离和表征。
可以用有机合成领域的技术人员已知的多种方式来制备本发明的化合物，可使用下述方法以及有机合成化学领域中已知的合成方法或通过本领域技术人员所了解的其变化形式来合成本发明化合物。优选方法包括但不限于下文所述的这些。在适用于所使用试剂盒材料和适用于所实现转变的溶剂或溶剂混合物中实施反应。有机合成领域的技术人员将理解，分子上存在的官能性与所提出的转变一致。这有时需要加以判断改变合成步骤的顺序或原料以获得期望的本发明化合物。
具体实施方式
实施例
通用过程
未包括制备途径时，本发明所用原料与试剂均为已知产品，可以按照本领域已知的方法合成，或者可通过购买市售产品获得。使用的市售试剂均不需进一步纯化。室温是指20-30℃。
反应实施例中无特殊说明，反应均在氮气氛下进行。氮气氛是指反应瓶连接一个约1L的氮气气球。
氢化反应通常抽真空，充入氢气，反复操作3次。氢气氛是指反应瓶连接一个约1L的氢气气球。
微波反应使用 Initiator+微波反应器。
本发明化合物的结构是通过核磁共振(NMR)和质谱(MS)来确定的。NMR位移(δ)以10-6(ppm)的单位给出。NMR的测定是用(Bruker AscendTM 500型)核磁仪，测定溶剂为氘代二甲基亚砜(DMSO-d6)，氘代氯仿(CDCl3),氘代甲醇(CD3OD)，内标为四甲基硅烷(TMS)。以下简写用于NMR信号的多重性：s＝单峰，brs＝宽峰，d＝二重峰，t＝三重峰，m＝多重峰。耦合常数以J值列出，以Hz测量。
LC-MS的测定使用Thermo液质联用仪(UltiMate 3000+MSQ PLUS)。HPLC的测定使用Thermo高压液相色谱仪(UltiMate 3000)。反相制备色谱使用Thermo(UltiMate 3000)反相制备色谱仪。快速柱层析使用艾杰尔(FS-9200T)自动过柱机，硅胶预装柱使用三泰预装柱。薄层层析硅胶板用烟台黄海HSGF254或青岛GF254硅胶板，薄层层析分离纯化产品采用的规格是0.4mm～0.5mm。
本发明中一些中间体的合成方法如下：
中间体1
中间体1由以下步骤制备：
第一步：将1-甲基-3,5-二硝基吡啶-2-酮Int-1a(1.0g,5.02mmol)溶于甲醇(50mL)中，依次加入氨甲醇溶液(7mol/L，8.61mL,60.27mmol)和1-甲基哌啶-4-酮Int-1b(625mg,5.52mmol)。反应混合物加热至50℃搅拌5小时。冷却至室温后静置48小时，减压浓缩反应液，残余物加入乙酸乙酯(50mL)后过滤。滤液减压浓缩后得到红色固体Int-1c(1.0g)，直接用于下一步反应。ESI-MS(m/z):194.4[M+H]+；1HNMR(500MHz,DMSO-d6)δ9.14(d,J＝2.5Hz,1H),8.36(d,J＝2.5Hz,1H),3.64(s,2H),3.02(t,J＝6.0Hz,2H),2.74(t,J＝6.0Hz,2H),2.39(s,3H)。
第二步：将上一步得到的化合物Int-1c(1.0g)溶于甲醇(30mL)中，加入10％Pd-C(400mg)，在氢气氛围下室温反应6小时。过滤除去钯碳，滤液浓缩得到黄色固体Int-1(800mg，收率94.70％)。ESI-MS(m/z):164.2[M+H]+。
中间体2
中间体2由以下步骤制备：
第一步：将化合物Int-1(100mg,0.61mmol)溶于醋酸(3mL)中，加入N-溴代丁二酰亚胺(109mg,0.61mmol)，反应混合物在室温下搅拌1小时。加入饱和碳酸氢钠水溶液淬灭反应直至不产生气泡，水相用甲醇/二氯甲烷(1/20,50mL×2)萃取，合并有机相，无水硫酸钠干燥，过滤浓缩得到化合物Int-2a(38mg，收率25％)。ESI-MS(m/z):242.3[M+H]+；1HNMR(500MHz,DMSO-d6)δ6.77(s,1H),5.25(s,2H),3.37(s,2H),2.69(t,J＝6.0Hz,2H),2.60(t,J＝6.0Hz,2H),2.32(s,3H)。
第二步：将化合物Int-2a(37mg,0.15mmol)溶于甲醇(1mL)中，加入碘化亚铜(3mg，0.015mmol)，1，10-菲啰啉(3mg，0.03mmol)和碳酸铯(99mg,0.30mmol)。反应混合物置换氮气后用微波加热至100℃搅拌2小时。反应冷却至室温，浓缩反应液，残余物用制备型薄层层析纯化(甲醇/二氯甲烷/三乙胺＝1/10/0.1)得到黄色固体Int-2(20mg，收率67％)。ESI-MS(m/z):194.5[M+H]+；1HNMR(500MHz,DMSO-d6)δ6.54(s,1H),4.68(s,2H),3.80(s,3H),3.30(s,2H),2.64(t,J＝5.6Hz,2H),2.59(t,J＝5.7Hz,2H),2.31(s,3H)。
中间体6
中间体6由以下步骤制备：
第一步：在0℃冰浴条件下，将甲酸(2.14g,46.57mmol,1.76mL)滴加至乙酸酐(3.17g,31.05mmol,2.93mL)中，然后升至室温搅拌1小时。接着将该混合液重新冷却至0℃，滴加至Int-2(500mg,2.59mmol)的四氢呋喃(10mL)溶液(0℃)中，然后升至室温搅拌30分钟。用二氯甲烷稀释反应液，用饱和碳酸氢钠溶液洗涤三次。有机相用无水硫酸钠干燥，过滤，浓缩。残留物用硅胶柱层析纯化(二氯甲烷/甲醇＝10/1)得到白色固体Int-6(550mg,收率96％)。ESI-MS(m/z):222.5[M+H]+。
中间体8
中间体8由以下步骤制备：
第一步：将化合物Int-8a(300mg，1.42mmol)溶于二氯甲烷(10mL)中，冰浴下加入m-CPBA(604mg，含量85％，2.98mmol)，加料完毕后冰浴下继续反应4小时，LCMS检测原料反应完全。反应液浓缩，残余物硅胶柱层析纯化得到淡黄色固体Int-8(300mg，收率86％)。ESI-MS(m/z):244.3[M+H]+。
中间体9
中间体9由以下步骤制备：
第一步：将化合物Int-6(230mg,1.04mmol)溶于无水DMF(10mL)中，冰浴下加入NaH(42mg，含量60％，1.04mmol)。混合物在室温下搅拌30分钟后，冷却至0℃，滴加Int-8(244mg，1.14mmol)的DMF(3mL)溶液。滴加完毕室温反应2小时，LCMS检测原料反应完全。将0.1N的NaOH溶液(1mL)加入到反应溶液中，室温搅拌1小时。将反应液倒入水(40mL)中，有黄色固体析出，过滤收集固体，干燥得到Int-9(230mg，产率62％)。ESI-MS(m/z):357.2[M+H]+。
中间体16
中间体16由以下步骤制备：
将化合物Int-9(500mg，1.4mmol)溶于二氯甲烷(20mL)中，0℃下缓慢滴加BBr3的二氯甲烷溶液(1M，1.68mL，4.2mmol)，滴加完毕，缓慢升至室温过夜，LCMS监测原料反应完全。反应液用甲醇淬灭，浓缩，残余固体用乙酸乙酯打浆，过滤，干燥得550mg化合物Int-16(HBr salt)，棕色固体，收率92.64％，ESI-MS(m/z):343.3[M+H]+。
实施例70
3-((8-((3-羟基-2,2-二甲基丙基)氨基吡啶并[3,4-d]嘧啶-2-基)氨基)-6-甲基-5,6,7,8-
四氢-1,6-萘啶-2(1H)-酮
化合物70由以下步骤制备：
第一步：将Int-16(50mg，118umol，HBr盐)溶于N-甲基吡咯烷酮(4mL)中，加入3-氨基-2,2-二甲基-1-丙醇(61mg，0.59mmol)和N,N-二异丙基乙胺(76mg,0.59mmol)。反应液用微波反应器加热至150℃搅拌4小时，LCMS检测反应完全。反应液浓缩，残余物用Prep-HPLC纯化得到黄色固体70(16mg，收率33％)。ESI-MS(m/z):410.3[M+H]+；1H NMR(500MHz,DMSO-d6)δ11.91(s,1H),9.22(s,1H),8.42(s,1H),8.22(s,1H),7.81(d,J＝5.5Hz,1H),7.23(s,1H),6.88(d,J＝5.5Hz,1H),5.06(t,J＝5.6Hz,1H),3.44(d,J＝5.8Hz,2H),3.34(s,2H),3.28(d,J＝5.0Hz,2H),2.59(s,4H),2.33(s,3H),0.95(s,6H)。
实施例76
(R)-6-甲基-3-((8-(2-甲基哌啶-1-基)吡啶并[3,4-d]哌啶-2-基)氨基)-5,6,7,8-四氢
-1,6-萘啶-2(1H)-酮
用R-2-甲基哌啶替换实施例70中第一步的3-氨基-2,2-二甲基-1-丙醇，用类似的方法和反应步骤，可以得到化合物76。ESI-MS(m/z):405.4[M+H]+；1H NMR(500MHz,DMSO-d6)δ11.97(s,1H),9.30(s,1H),8.41(s,1H),8.08(s,1H),8.03(d,J＝5.3Hz,1H),7.19(d,J＝5.3Hz,1H),5.13(br s,1H),4.15-4.06(m,1H),3.28-3.22(m,2H),2.65-2.55(m,4H),2.35(s,3H),2.02-1.94(m,1H),1.80-1.75(m,2H),1.70-1.57(m,3H),1.10(d,J＝6.8Hz,3H)。
实施例77
6-甲基-3-((8-(((1-甲基环丙基)甲基)氨基)吡啶并[3,4-d]嘧啶-2-基)氨基)-5,6,7,8-四氢-1,6-萘啶-2(1H)-one
用1-甲基环丙基乙胺替换实施例70中第一步的3-氨基-2,2-二甲基-1-丙醇，用类似的方法和反应步骤，可以得到化合物77。ESI-MS(m/z):392.2[M+H]+；1H NMR(500MHz,DMSO-d6)δ11.95(s,1H),9.23(s,1H),8.42(s,1H),8.23(s,1H),7.83(d,J＝5.6Hz,1H),6.90(d,J＝5.7Hz,1H),6.74(br s,1H),3.45(d,J＝5.7Hz,2H),3.34(s,2H),2.64-2.56(m,4H),2.34(s,3H),1.17(s,3H),0.63-0.57(m,2H),0.36-0.32(m,2H)。
HPK1抑制剂生物学筛选和结果
试验例1：化合物对HPK1激酶活性抑制能力的检测(方法1)
所需使用试剂如下
实验步骤
具体操作如下：配置酶促反应体系缓冲液(10mM MOPS，pH 7.2，5mMβ-glycerol-phosphate，10mM MgCl2，0.8mM EDTA，2mM EGTA，0.1mM DTT)；将测试的化合物(配于DMSO中1mM的化合物储液)用缓冲液稀释至为60uM最高浓度(包含6％DMSO)，并配置60μM浓度起始用包含6％DMSO的缓冲液进行5倍稀释共计8个点的梯度浓度的化合物；随后使用缓冲液将HPK1激酶稀释至30nM。在Greiner 384孔微孔板(货号：784075)中每孔加入2μl的HPK1激酶稀释液，对照孔中补充2μl缓冲液；短暂离心后在反应孔中加入1μl的稀释化合物，对照孔中加入1μl包含6％DMSO的缓冲液；短暂离心后置于25℃恒温孵育箱(上海一恒科学仪器有限公司，货号：LRH-150)中孵育20min。在每孔中加入3μl反应底物(溶解于蒸馏水中的10μMMBP和20μM ATP)，短暂离心后置于25℃恒温孵育箱中孵育60min，采用ADP-Glo KinaseAssay Kit检测酶促反应活性，ADP-Glo Kinase Assay Kit检测都依据试剂盒的操作说明进行。数据采用化合物的半数抑制浓度IC50描述。
| 化合物编号 | IC50(nM) |
| 70 | 0.29 |
| 76 | <0.1 |
| 77 | <0.1 |
试验例3：化合物对小鼠脾脏细胞分泌细胞因子白介素-2(IL-2)激动能力的检测(方法3)
所需使用试剂及细胞如下
实验试剂：
实验动物：
实验步骤
具体操作如下：将化合物粉末用DMSO溶解至10mM，取2μl化合物加入到998μlRPMI1640培养基(此试验中均含10％FBS)中，涡旋混匀后为最高浓度点。用0.2％DMSO培养基3倍逐渐稀释化合物溶液，共8个浓度点。以含浓度为0.1％DMSO的RPMI 1640培养基溶液处理作为对照。在康宁96孔细胞培养板(货号：3599)中每孔加入小鼠105脾脏细胞，随后加入等量体积的化合物稀释液，对照组加入含0.2％DMSO的RPMI 1640培养基，置于37℃细胞培养箱(Thermo Fisher Scientific，型号：3111)孵育1h。随后加入终浓度为0.4μg/mlConcanavalin A，置于37℃细胞培养箱孵育24h。采用Mouse IL-2DuoSet ELISA KIT检测细胞上清液中的IL-2含量，Mouse IL-2DuoSet ELISA检测依据试剂盒的操作说明进行。数据采用化合物的刺激信号与0.1％DMSO的信号的最高倍数比值描述。
NA:表示未检测到IL-2的释放增强。
试验例4：化合物对DC2.4细胞分泌细胞因子白介素-6(IL-6)激动能力的检测(方法3)
所需使用试剂及细胞如下
实验试剂：
实验细胞：
实验步骤
具体操作如下：将化合物粉末用DMSO溶解至10mM，取2μl化合物加入到998μlRPMI1640培养基(此试验中均含10％FBS)中，涡旋混匀后为最高浓度点。用0.2％DMSO培养基3倍逐渐稀释化合物溶液，共8个浓度点。以含浓度为0.1％DMSO的RPMI 1640培养基溶液处理作为对照。在康宁96孔细胞培养板(货号：3599)中每孔加入105DC2.4细胞，随后加入等量体积的化合物稀释液，对照组加入含0.2％DMSO的RPMI 1640培养基，置于37℃细胞培养箱(Thermo Fisher Scientific，型号：3111)孵育1h。随后加入终浓度为3.2ng/ml LPS，置于37℃细胞培养箱孵育24h。采用Mouse IL-6DuoSet ELISA KIT检测细胞上清液中的IL-2含量，Mouse IL-6DuoSet ELISA检测依据试剂盒的操作说明进行。数据采用化合物的刺激信号与0.1％DMSO的信号的最高倍数比值描述。
NA:表示未检测到IL-6的释放增强。
试验例5：化合物对PBMC分泌细胞因子白介素-2(IL-2)激动能力的检测(方法5)
所需使用试剂及细胞如下
实验试剂：
实验细胞：
实验步骤
具体操作如下：将化合物粉末用DMSO溶解至10mM，取2μl化合物加入到998μlRPMI1640培养基(此试验中均含10％FBS)中，涡旋混匀后为最高浓度点。用0.2％DMSO培养基3倍逐渐稀释化合物溶液，共8个浓度点。以含浓度为0.1％DMSO的RPMI 1640培养基溶液处理作为对照。在康宁96孔细胞培养板(货号：3599)中每孔加入1×105PBMC细胞，随后加入等量体积的化合物稀释液，对照组加入含0.2％DMSO的RPMI 1640培养基，置于37℃细胞培养箱(Thermo Fisher Scientific，型号：3111)孵育1h。随后加入终浓度为0.1μg/ml Anti-human CD3Antibody和1μg/ml Anti-human CD28 Antibody抗体，置于37℃细胞培养箱孵育24h。采用Human IL-2DuoSet ELISA KIT检测细胞上清液中的IL-2含量，Human IL-2DuoSetELISA检测依据试剂盒的操作说明进行。数据采用化合物的刺激信号与0.1％DMSO的信号的最高倍数比值描述。
NA:表示未检测到IL-2的释放增强。
Claims (3)
1.具有如下结构的化合物及其药学上可接受的盐、同位素衍生物或者立体异构体：
。
2.药物组合物，其包括权利要求1所述的化合物以及药学上可用的载体。
3.权利要求1所述的化合物或其药学上可接受的盐、同位素衍生物、立体异构体或权利要求2所述的药物组合物在制备用于预防和/或治疗癌症、肿瘤、炎症性疾病、自身免疫性疾病或免疫介导性疾病的药物中的用途。
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011168944 | 2020-10-28 | ||
| CN2020111689441 | 2020-10-28 | ||
| PCT/CN2021/126307 WO2022089398A1 (zh) | 2020-10-28 | 2021-10-26 | 一种高活性的hpk1激酶抑制剂 |
| CN202180070254.9A CN116685585A (zh) | 2020-10-28 | 2021-10-26 | 一种高活性的hpk1激酶抑制剂 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180070254.9A Division CN116685585A (zh) | 2020-10-28 | 2021-10-26 | 一种高活性的hpk1激酶抑制剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116731046A true CN116731046A (zh) | 2023-09-12 |
Family
ID=81381527
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310687571.6A Pending CN116731046A (zh) | 2020-10-28 | 2021-10-26 | 一种高活性的hpk1激酶抑制剂 |
| CN202310686054.7A Pending CN116751217A (zh) | 2020-10-28 | 2021-10-26 | 一种高活性的hpk1激酶抑制剂 |
| CN202310688656.6A Pending CN116874503A (zh) | 2020-10-28 | 2021-10-26 | 一种高活性的hpk1激酶抑制剂 |
| CN202180070254.9A Pending CN116685585A (zh) | 2020-10-28 | 2021-10-26 | 一种高活性的hpk1激酶抑制剂 |
| CN202310686704.8A Pending CN117024445A (zh) | 2020-10-28 | 2021-10-26 | 用于制备hpk1激酶抑制剂的化合物及其合成方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310686054.7A Pending CN116751217A (zh) | 2020-10-28 | 2021-10-26 | 一种高活性的hpk1激酶抑制剂 |
| CN202310688656.6A Pending CN116874503A (zh) | 2020-10-28 | 2021-10-26 | 一种高活性的hpk1激酶抑制剂 |
| CN202180070254.9A Pending CN116685585A (zh) | 2020-10-28 | 2021-10-26 | 一种高活性的hpk1激酶抑制剂 |
| CN202310686704.8A Pending CN117024445A (zh) | 2020-10-28 | 2021-10-26 | 用于制备hpk1激酶抑制剂的化合物及其合成方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230399327A1 (zh) |
| CN (5) | CN116731046A (zh) |
| TW (1) | TW202216712A (zh) |
| WO (1) | WO2022089398A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102650496B1 (ko) | 2018-10-31 | 2024-03-26 | 길리애드 사이언시즈, 인코포레이티드 | Hpk1 억제제로서의 치환된 6-아자벤즈이미다졸 화합물 |
| CN117105933A (zh) | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA200900819A1 (ru) * | 2006-12-22 | 2010-02-26 | Новартис Аг | Хиназолины для ингибирования pdk1 |
| WO2009084695A1 (ja) * | 2007-12-28 | 2009-07-09 | Carna Biosciences Inc. | ２－アミノキナゾリン誘導体 |
| US20100121052A1 (en) * | 2008-06-20 | 2010-05-13 | Rama Jain | Novel compounds for treating proliferative diseases |
| KR102338568B1 (ko) * | 2013-12-06 | 2021-12-13 | 엠와이씨헌터 테라퓨틱스, 아이엔씨. | 퀴나졸린 유도체 |
| CN109721620B (zh) * | 2017-10-27 | 2022-05-13 | 药捷安康(南京)科技股份有限公司 | Hpk1抑制剂及其用途 |
| US20220389037A1 (en) * | 2019-07-04 | 2022-12-08 | Qilu Regor Therapeutics Inc. | Hpk1 inhibitors and uses thereof |
| WO2021088787A1 (zh) * | 2019-11-07 | 2021-05-14 | 南京正大天晴制药有限公司 | 作为axl抑制剂的喹唑啉类化合物 |
-
2021
- 2021-10-26 CN CN202310687571.6A patent/CN116731046A/zh active Pending
- 2021-10-26 US US18/034,367 patent/US20230399327A1/en active Pending
- 2021-10-26 CN CN202310686054.7A patent/CN116751217A/zh active Pending
- 2021-10-26 CN CN202310688656.6A patent/CN116874503A/zh active Pending
- 2021-10-26 CN CN202180070254.9A patent/CN116685585A/zh active Pending
- 2021-10-26 WO PCT/CN2021/126307 patent/WO2022089398A1/zh active Application Filing
- 2021-10-26 CN CN202310686704.8A patent/CN117024445A/zh active Pending
- 2021-10-27 TW TW110139899A patent/TW202216712A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN116751217A (zh) | 2023-09-15 |
| TW202216712A (zh) | 2022-05-01 |
| US20230399327A1 (en) | 2023-12-14 |
| WO2022089398A1 (zh) | 2022-05-05 |
| CN116685585A (zh) | 2023-09-01 |
| CN116874503A (zh) | 2023-10-13 |
| CN117024445A (zh) | 2023-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114751903B (zh) | 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途 | |
| JP7033141B2 (ja) | メニン－ｍｌｌ相互作用の縮合二環式阻害剤 | |
| TWI478714B (zh) | 作為Ｊａｎｕｓ激酶３（ＪＡＫ３）抑制劑之含氮雜芳基衍生物類 | |
| EA017442B1 (ru) | ПРОИЗВОДНЫЕ 2-АРИЛ-6-ФЕНИЛИМИДАЗО[1,2-a]ПИРИДИНОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| WO2011101429A1 (en) | Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use | |
| MX2014003800A (es) | Derivado de pirazoloquinolina. | |
| JP2010523522A (ja) | Ｊａｋ３阻害剤としてのピロロピリミジン誘導体 | |
| CN116731046A (zh) | 一种高活性的hpk1激酶抑制剂 | |
| AU2013354552B2 (en) | Substituted pyridopyrazines as Syk inhibitors | |
| EP3157925A1 (en) | Imidazo-pyridazne derivatives as casein kinase 1 delta/epsilon inhibitors | |
| TWI826509B (zh) | 作為vanin抑制劑之雜芳族化合物 | |
| JP7018944B2 (ja) | ＰＤＥ２阻害剤としての［１，２，４］トリアゾロ［１，５－ａ］ピリミジン化合物 | |
| JP2023528925A (ja) | ピリドンピリミジン系誘導体、その調製方法及びその医薬的応用 | |
| JP2021532100A (ja) | さらなる置換トリアゾロキノキサリン誘導体 | |
| CN115298179A (zh) | Mettl3调节剂 | |
| HUE024989T2 (en) | Azaindole derivatives as ABI and SRC protein kinase inhibitors | |
| EP3907225A1 (en) | Imidazopyridine derivative compounds and use of same | |
| KR20170003521A (ko) | 3 고리성 화합물 및 jak 저해제 | |
| JP2023145547A (ja) | Ｃｄ７３阻害剤、その製造方法と応用 | |
| CA2813144C (en) | Chromene derivatives | |
| CN113698391A (zh) | 4-氨基嘧啶或2-氨基三嗪类化合物及其制备方法 | |
| CN116854687A (zh) | Hpk1激酶抑制剂化合物 | |
| JP2021011492A (ja) | ４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オン化合物 | |
| JP2021521269A (ja) | 疼痛及び炎症の治療に有用なヘキサデカヒドロ−１Ｈ−シクロペンタ［ａ］フェナントレン誘導体 | |
| WO2024104282A1 (zh) | 一种1H-吡咯并[2,3-b]吡啶衍生物、其制备方法及其在医药上的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |